Theorem Clinical Research has announced the formation of a strategic alliance with Decision Driver Analytics
Theorem Clinical Research
has announced the formation of a strategic alliance with
Decision Driver Analytics
(DDA) that will integrate health economics and outcomes research (HEOR), predictive modeling and definitive analysis to maximize return on investment for pharmaceutical and medical device research programs.
“The clinical studies that may prove a scientific point are really only one aspect of a successful drug or medical device development program,” said
John Potthoff, president and CEO of Theorem Clinical Research
. “Decision Driver Analytics’ product life cycle value analysis and exceptional economic insight help clients make high-value decisions with confidence throughout the entire development process.”
Decision Driver Analytics was founded in 2006 by Elizabeth Brooks, Ph.D., to provide accessible health economics analysis and strategies that can be used to drive key product decisions for manufacturers and developers. A recognized expert in her field, Brooks has designed numerous health economics models and market development programs. Backed by a team of specialists including health economists, epidemiologists, biostatisticians, medical writers and reimbursement experts, Brooks is known for an ability to make statistical results understandable and actionable.
“Knowing the right answers to key questions at critical decision points in the development process can make the difference between having the latest blockbuster or an expensive failure,” Potthoff said. “We believe this alliance helps drive projects for clients in ways that will achieve both regulatory and marketing success.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Real-World Data Show 99% Efficacy for Apretude in HIV Prevention with High Adherence, Reduced Stigma
October 16th 2024Real-world data presented at IDWeek 2024 show Apretude (cabotegravir long-acting) is more than 99% effective in preventing HIV infection, with high adherence rates, reduced stigma and anxiety, and broad acceptability.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.